Axcelis Technologies, Inc. (ACLS) Stock Price & How to Invest

Last updated November 2026

Short answer

You can invest in Axcelis Technologies (ACLS) by buying shares or fractional shares at any major broker, through a semiconductor or chip-equipment ETF that holds it, or as one holding in a thematic basket. Axcelis is a specialized US maker of ion implantation systems (its Purion platform) used to manufacture semiconductors, with heavy exposure to power chips, mature-node, and increasingly memory. The story now also hinges on its pending all-stock merger with Veeco, announced October 2025, to form a larger US wafer-fabrication-equipment supplier; the close has slipped to an expected end of the first quarter of 2027, pending regulatory clearance in China. As of November 20, 2026 the shares were ~$90.49 (market cap ~$2.8 billion), up ~5% year to date but ~28% below where they stood three months earlier.

ACLS stock price

As of 2026-11-20, Axcelis Technologies, Inc. (ACLS) last closed at $90.26, up 17.4% over the past year. Over the past 52 weeks it has traded between $76.88 and $191.60.

ACLS last close
$90.26
1 day
-9.69%
1 month
-22.58%
1 year
+17.40%
52-week range
$76.88 to $191.60
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Axcelis Technologies, Inc.'s investor relations page. Walnut is informational, not investment advice.

ACLS key stats

At $90.26 on November 20, 2026, Axcelis Technologies, Inc. (ACLS) has a market cap of $2.8B and a P/E of 26.9 on trailing earnings (14.6 on forward earnings).

Market cap
$2.8B
P/E (trailing)
26.9
P/E (forward)
14.6
EPS (trailing 12 months)
$3.36
Price to book
2.5
Beta
1.89

Market cap, P/E and yield are measured at the $90.26 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Axcelis Technologies, Inc. (ACLS)?

The last two weeks for Axcelis Technologies, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • ACLS closed at $90.26 on November 20, 2026, down 13.6% over the past five trading days (from $104.42).

Axcelis Technologies, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Axcelis Technologies, Inc. (ACLS) latest quarter

Axcelis Technologies reported revenue of $238 million for Q3 2026, up 11% from a year earlier (Axcelis Technologies, Nov 5, 2026).

Revenue
$238 million
up 11% from a year earlier
Diluted EPS (GAAP)
$1.21
up 46% from a year earlier
Systems
$145 million
up 1% from a year earlier

Source: Axcelis Technologies Q3 2026 results, Nov 5, 2026. Full earnings breakdown

What does Axcelis Technologies, Inc. (ACLS) do?

Axcelis Technologies designs and sells ion implantation equipment for the semiconductor industry, along with the aftermarket service and spare parts (its CS&I business) that keep those tools running. Ion implantation is the process step that shoots charged atoms into silicon wafers to change their electrical properties, and it is essential to making almost every chip. The company's Purion product family serves a wide range of end markets, including power devices (notably silicon carbide chips used in electric vehicles and industrial systems), image sensors, general mature-node logic, and memory such as DRAM and high-bandwidth memory (HBM). Ion implantation makes up the large majority of revenue, so Axcelis is a fairly pure play on that one process step rather than a diversified equipment giant.

The investment picture is that of a small, cyclical equipment supplier riding chip-industry capital-spending cycles. Revenue fell from about $1.02 billion in 2024 to roughly $839 million in 2025 as the silicon carbide and power markets slowed and Chinese customers digested earlier orders, and net income compressed accordingly. Early 2026 results showed stabilization, and the second quarter turned to growth: revenue rose ~10.6% year over year to ~$215 million and adjusted EPS of ~$1.06 beat a ~$0.89 consensus. Management lifted its 2026 outlook from roughly flat revenue to mid-single-digit growth, citing DRAM and HBM demand. The third quarter, reported November 5, extended the recovery: revenue of ~$238 million rose ~11.3% year over year, EPS of ~$1.26 beat a ~$1.11 consensus, system bookings reached ~$222 million for a book-to-bill of about 1.5 (the highest since late 2023), and the CS&I aftermarket business posted a record ~$93 million. Gross margin of ~41.2% came in below the ~43% outlook, which the company attributed mainly to a sharp rise in the Korean won, and the shares fell about 6% on the day. The biggest structural change is the pending merger with Veeco Instruments (announced October 2025, an all-stock deal valued around $4.4 billion combined), which would pair Axcelis ion implantation with Veeco laser annealing, advanced-packaging lithography, and epitaxy to create what the companies describe as the fourth-largest US-based wafer-fabrication-equipment supplier.

As of November 20, 2026 the stock closed at ~$90.49, up ~5% year to date and ~22% over one year, but down ~15% over the past month and well off a 52-week high of ~$193.78. In September Axcelis announced a $35 million, 200,000-square-foot ion implantation manufacturing plant in Pyeongtaek, Korea, with production targeted for the second half of 2028. The company still trades on its own as ACLS: on the third-quarter call management said the Veeco deal is now expected to close by the end of the first quarter of 2027, pending regulatory clearance in China. China was about 46% of third-quarter revenue. Fourth-quarter consensus sits near ~$1.50 EPS on ~$275 million of revenue.

What's driving Axcelis Technologies, Inc. (ACLS)?

1. Memory recovery (DRAM and HBM).

After a stretch dominated by power and mature-node demand, management flagged meaningful acceleration in Memory in early 2026, with DRAM and HBM highlighted as a standout showing strong sequential growth. The AI-driven buildout of high-bandwidth memory is a new demand pool for Axcelis implant tools. This shift helps offset softness in the silicon carbide and power markets that weighed on 2024 and 2025. Memory made up about 14% of second-quarter 2026 shipped systems revenue and about 20% of third-quarter system sales (mostly DRAM), and management said it expects meaningful year-over-year memory growth in 2026 with momentum into 2027.

2. Power devices and silicon carbide.

Axcelis built a strong position supplying implant tools for silicon carbide power chips used in electric vehicles and industrial applications. That market cooled sharply as EV growth slowed and customers worked down capacity, pressuring revenue. A recovery in SiC and power investment would be a direct tailwind, but the timing depends on end-market demand Axcelis does not control.

3. Pending Veeco merger.

The proposed all-stock combination with Veeco (roughly $4.4 billion combined value, Axcelis holders owning about 58 percent, originally expected to close in the second half of 2026) would broaden the product portfolio well beyond ion implantation. Stockholders have approved the deal, and management targets cost and revenue synergies. Integration risk, regulatory approvals, and the loss of the pure-play profile are the trade-offs. On the November 2026 earnings call management said the close had been delayed and is now expected by the end of the first quarter of 2027, pending regulatory clearance in China, a market that supplied about 46% of Axcelis' third-quarter revenue. Until then ACLS trades independently.

4. Aftermarket and services (CS&I).

Axcelis has a growing installed base of Purion systems, which generates recurring revenue from spare parts, upgrades, and service. This CS&I business is less cyclical than new-tool sales, helped cushion results during the equipment downturn, and reached a record ~$93 million of revenue in the third quarter of 2026. A larger installed base over time supports a more stable revenue floor beneath the lumpier systems business. Axcelis is also adding manufacturing capacity close to customers: a $35 million plant in Pyeongtaek, Korea, announced in September 2026, is slated to begin production in the second half of 2028.

What are the risks to Axcelis Technologies, Inc. (ACLS)?

Axcelis is a small, highly cyclical company whose results swing with semiconductor capital-spending cycles it does not control, and its concentration in ion implantation means a slump in that step or in key end markets (like silicon carbide power chips) hits it hard, as the 2024 to 2025 revenue decline showed. A large share of demand comes from China (about 46% of third-quarter 2026 revenue), exposing the company to export controls, tariffs, and geopolitical tension that could restrict sales. The pending Veeco merger adds execution risk: its close has slipped to an expected end of the first quarter of 2027 while it awaits clearance in China, faces integration challenges, and could dilute or distract even if it closes. Margins are a fresh concern: second-quarter 2026 non-GAAP gross margin fell to ~42.7% from ~45.2% and non-GAAP operating margin to ~14.7% from ~17.7%, and third-quarter gross margin of ~41.2% missed the ~43% outlook, mainly on currency moves in the Korean won, so a beat on revenue and EPS still sent the shares lower. Customer concentration, competition from much larger equipment makers, and the general volatility of a roughly $2.8 billion market-cap chip-equipment stock, which swung between ~$73.60 and ~$193.78 over the past year and fell ~28% in the three months to November 20, 2026, round out the risks.

What is the Axcelis Technologies, Inc. (ACLS) forecast?

3 analysts publish price targets on ACLS, averaging $132.00 as of November 2026, or +46.2% against the $90.26 share price on November 20, 2026. The published targets run from $116.00 to $140.00, a narrow spread, and the ratings split 2 buy, 2 hold, 1 sell. Over the last six months there have been 2 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ACLS forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is ACLS a buy or a sell?

We give no verdict on Axcelis Technologies, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Memory recovery (DRAM and HBM). After a stretch dominated by power and mature-node demand, management flagged meaningful acceleration in Memory in early 2026, with DRAM and HBM highlighted as a standout showing strong sequential growth. The most optimistic published target, $140.00, assumes this works close to its best case.

The case against. Axcelis is a small, highly cyclical company whose results swing with semiconductor capital-spending cycles it does not control, and its concentration in ion implantation means a slump in that step or in key end markets (like silicon carbide power chips) hits it hard, as the 2024 to 2025 revenue decline showed. The most pessimistic target, $116.00, is roughly what ACLS is worth if this bites instead.

Read the full bull and bear case on ACLS, including what would have to change to break either one. Walnut is not an investment adviser.

Has Axcelis Technologies, Inc. (ACLS) split its stock?

No. Axcelis Technologies, Inc. (ACLS) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Axcelis Technologies, Inc. (ACLS) valued?

Market cap, P/E and dividend yield at today's price are in the ACLS key stats above. The business figures below come from Axcelis Technologies, Inc.'s reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$890 million (Q3 2026 up ~11.3% yoy)
  • Revenue (FY2025): ~$839 million
  • Net income (TTM): ~$105 million (~12% margin)
  • Q3 2026 revenue: ~$238 million (EPS ~$1.26 vs ~$1.11 est.)
  • Q3 2026 system bookings: ~$222 million (book-to-bill ~1.5)
  • Cash / debt: ~$472 million / ~$70 million

As of November 2026: At ~$90.49 on November 20, 2026, Axcelis trades at about 27x trailing earnings, which are depressed, and ~15x forward estimates that assume EPS rises from ~$4.54 in 2026 to ~$6.20 in 2027. The stock fell ~28% over three months as gross margins slipped and the Veeco close was pushed out, even though revenue grew and bookings jumped. A net cash balance of roughly $400 million cushions the cycle. All figures are approximate and change with each quarter and the market.

Who competes with Axcelis Technologies, Inc. (ACLS)?

Ion implantation rivals

Applied Materials is the dominant competitor in ion implantation and the primary head-to-head rival for Axcelis Purion systems, giving a much larger, diversified player a direct presence in Axcelis core market.

Broad wafer-fab-equipment makers

Larger semiconductor-equipment companies such as Lam Research, KLA, ASML, and Tokyo Electron compete for the same customer capital budgets across other process steps, and set the scale that Axcelis (and a merged Axcelis-Veeco) is trying to close some of the gap on.

Merger partner and adjacent tools

Veeco Instruments is Axcelis pending merger partner rather than a rival, bringing laser annealing, advanced-packaging lithography, and epitaxy; together they would form a mid-tier US supplier competing across a wider slice of the fab.

What stocks are similar to Axcelis Technologies, Inc. (ACLS)?

Other names that sit close to ACLS: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Axcelis Technologies, Inc. (ACLS)

There are three common ways to get ACLS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ACLS sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ACLS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Axcelis Technologies, Inc. (ACLS)

Axcelis is a niche, cyclical semiconductor-equipment maker whose ion implantation franchise is digesting a power-chip downturn while memory demand accelerates, and whose next chapter depends on closing and integrating the Veeco merger, now expected by the end of the first quarter of 2027. In November 2026 the stock traded near 15x forward earnings after falling despite a third-quarter beat and the strongest bookings quarter in nearly three years.

More on Axcelis Technologies, Inc. (ACLS)

Whether ACLS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ACLS a buy or a sell?, and where the stock could go from here in the ACLS stock forecast.

For income investors, whether ACLS pays a dividend and how the payout looks is covered in does ACLS pay a dividend? And to weigh ACLS against a peer, read the full side-by-side comparisons: ACLS vs AMAT and ACLS vs LRCX.

Wondering how ACLS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Axcelis Technologies, Inc.

Ask Walnut's AI anything about ACLS and see how it fits what you own.

FAQ

What does Axcelis Technologies do?

+

Axcelis designs and sells ion implantation equipment (its Purion platform) used to manufacture semiconductors, plus the aftermarket parts and service that support those tools. Ion implantation is an essential step in making almost every chip.

Is ACLS a semiconductor stock?

+

Yes. Axcelis is a semiconductor capital-equipment company, meaning it sells the machines chipmakers use rather than the chips themselves. Its fortunes track industry capital-spending cycles across power, mature-node, image-sensor, and memory customers.

How does Axcelis make money?

+

The large majority of revenue comes from selling ion implantation systems, with the rest from its CS&I business (customer service, spare parts, upgrades, and used-tool sales) tied to its installed base. The service revenue is more recurring and less cyclical than new-tool sales.

What is the Axcelis and Veeco merger?

+

Announced in October 2025, it is an all-stock combination valued around $4.4 billion that would merge Axcelis ion implantation with Veeco laser annealing, packaging lithography, and epitaxy. Axcelis holders would own about 58 percent, and the deal was first expected to close in the second half of 2026. In November 2026 management said closing is now expected by the end of the first quarter of 2027, pending regulatory clearance in China; until then ACLS trades on its own.

Why did Axcelis revenue decline recently?

+

Revenue fell from about $1.02 billion in 2024 to roughly $839 million in 2025 mainly because the silicon carbide and power-chip markets slowed and some Chinese customers worked down earlier orders. These are the cyclical demand swings typical of chip-equipment suppliers. Growth has since returned: second-quarter 2026 revenue rose ~10.6% year over year to ~$215 million, third-quarter revenue rose ~11.3% to ~$238 million, and management expects mid-single-digit revenue growth for 2026.

Does Axcelis pay a dividend?

+

Axcelis has historically not paid a regular dividend, instead directing cash toward the business and share repurchases. Investors should confirm the current policy with the company's latest filings, since capital-return plans can change. As of November 2026, Yahoo Finance data showed no dividend.

What are the main risks with ACLS?

+

Key risks include the cyclicality of chip-equipment demand, concentration in ion implantation and specific end markets like silicon carbide, exposure to China (about 46% of third-quarter 2026 revenue) and export controls, and execution risk around closing and integrating the Veeco merger, whose close has slipped to an expected end of the first quarter of 2027. It is also a relatively small, volatile stock.

How can I invest in Axcelis?

+

You can buy ACLS shares or fractional shares through any major US broker, gain exposure through a semiconductor or chip-equipment ETF that holds it, or include it as one position in a thematic basket. Walnut is not an investment adviser, so weigh how it fits your own goals and risk tolerance.

How did Axcelis do in its latest quarter?

+

In the third quarter of 2026, reported November 5, Axcelis posted revenue of ~$238 million, up ~11.3% year over year, net income of ~$38 million and EPS of ~$1.26, ahead of a ~$1.11 consensus. System bookings of ~$222 million gave a book-to-bill of about 1.5, the highest since late 2023, and CS&I revenue hit a record ~$93 million. Gross margin of ~41.2% missed the ~43% outlook, mainly on the Korean won, and the shares fell about 6% that day. Fourth-quarter consensus is ~$1.50 EPS on ~$275 million of revenue.

How has ACLS stock performed in 2026?

+

ACLS closed at ~$90.49 on November 20, 2026, up about 5% year to date and ~22% over one year. It has been volatile, ranging from ~$73.60 to ~$193.78 over 52 weeks and falling ~28% over the three months to November 20 as investors focused on margin pressure and a later Veeco close. The three analysts in Yahoo Finance's data had a mean target of ~$132, and B. Riley cut its target to $140 from $165 after the third-quarter report.

When will the Axcelis and Veeco merger close?

+

On the November 2026 third-quarter call, Axcelis said the all-stock merger with Veeco had been delayed and is now expected to close by the end of the first quarter of 2027, pending regulatory clearance in China. Stockholders have already approved it. The timing is a company expectation, not a certainty, and depends on that approval.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Axcelis Technologies, Inc.'s investor relations page or your broker before making investment decisions.